Af­ter painful flop late last year, Al­lakos re­veals new PhI­II da­ta and piv­ots to new in­di­ca­tions

Sev­er­al years af­ter se­cur­ing $100 mil­lion cash in an NEA-led mega round to pur­sue its lead drug in cer­tain al­ler­gic and in­flam­ma­to­ry dis­eases, one-time high …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER